Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines
January 31, 2019 08:30 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed...
Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
January 16, 2019 08:30 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of...
Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta™ for M207
December 12, 2018 08:30 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food...
Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update
November 14, 2018 16:05 ET
|
Zosano Pharma Corporation
Selected a contract manufacturer for commercial launch of M207Completed first required data set in long-term safety study of M207Appointed Greg Kitchener as Chief Financial Officer FREMONT,Calif.,...
Zosano Pharma to Host Conference Call on Third Quarter 2018 Financial Results and Provide Operational Update
November 07, 2018 16:30 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host...
Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study
October 23, 2018 08:30 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that more than 150...
Zosano Pharma to Host Key Opinion Leader Meeting on New Treatments for Migraine and the Migraine Patients’ Perspective
October 18, 2018 08:00 ET
|
Zosano Pharma Corporation
Live webcast of the event available for analysts and investors FREMONT, Calif., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq: ZSAN) (“Zosano” or the “Company”), a...
Zosano Appoints New Chief Financial Officer
October 16, 2018 08:30 ET
|
Zosano Pharma Corporation
Seasoned financial and operational executive further strengthens management team FREMONT, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the...
Zosano Pharma Engages Contract Manufacturer as Part of the Commercialization Strategy for M207
October 03, 2018 08:30 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing...
Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment
September 26, 2018 08:30 ET
|
Zosano Pharma Corporation
FREMONT, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing...